New pill targets Hard-to-Treat cancers in groundbreaking first trial
NCT ID NCT06299839
Summary
This is the first study in people testing an experimental pill called PAS-004. It aims to find a safe dose and understand side effects for adults with advanced solid tumors that have specific genetic mutations (RAS, NF1, or RAF) and have run out of standard treatment options. Participants will take the pill daily for up to two years while doctors closely monitor their health and the drug's effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu
RECRUITINGBucharest, 022328, Romania
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Oncology Prof. Dr. Ion Chiricuta
RECRUITINGCluj-Napoca, RO-400015, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MBAL Sveta Sofia
RECRUITINGSofia, 1404, Bulgaria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGAustin, Texas, 78758, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.